Analysts believe hVIVO PLC (AIM:HVO), the scientific trials company, is in a strong position to win additional contracts after sealing a £6.3 million deal to research treating the common cold.
hVIVO will conduct the research using the human challenge study model for an unnamed biotechnology firm.
Plexus Holdings PLC (AIM:POS) shares jumped 10% then fell into the red after it announced a new, expanded IP licence agreement with SLB (previously Schlumberger) replacing the previous surface production wellhead licence agreement with Cameron (an SLB company) for a cash consideration of US$5.2 million.
The fact that the new licence agreement is royalty-free may have led to the swing in the shares, but broker Cavendish pointed out that Plexus had moved its focus away from the larger-volume, lower-cost surface production wellhead market.
Diversified Energy Company PLC (LSE:DEC, OTCQX:DECPF) has confirmed the closing of what it described as a “value adding asset sale”, which sees the disposal of producing assets in Appalachia to a special purpose vehicle (SPV), 20% owned by DEC, in a deal that generates US$200 million of proceeds.
Specifically, the assets were transferred into the SPV and the company subsequently sold an 80% stake in the vehicle, whilst retaining 20% and operatorship of the assets.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of a unique diagnostic focused on circulating tumour cells (CTCs) associated with cancer, has landed a contract with Eisai Inc, the Japanese pharma group, worth US$250,000.
The pilot study will utilise ANGLE’s Portrait HER2 assay in a phase II examination of the HER2 targeting antibody-drug conjugate (ADC), BB-1701.
Plexus Holdings PLC (AIM:POS) has agreed to expand the wellhead technology licence deal with SLB (Schlumberger) for a cash payment of US$5.2 million (£4.1 million).
The new surface production wellhead licence acquired by SLB is a perpetual royalty-free licence for POS-GRIP technology and HG seal technology plus any improvements, enhancements, or derivatives to the technology for surface wellhead production applications for all pressure and size ranges.
hVIVO PLC, a specialist in clinical trials for infectious and respiratory diseases, has announced a £6.3 million contract with an unnamed biotechnology client to conduct a study to test an antiviral for the common cold using a human challenge model.
The phase IIa trial, set to begin in the second half of 2024, will take place at the company's advanced quarantine facilities in Canary Wharf.